Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access